Drugs / Sodium picosulfate/magnesium citrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT03965182 Comparator | Jun 2019 → May 2020 | — | Dalin Tzu Chi General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium picosulfate/magnesium citrate | “Sodium picosulfate/magnesium citrate (SPMC) is generally better tolerated than PEG” NCT03965182 ↗ |
| Known as | SPMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03965182 ↗ |